Grace Therapeutics Inc.

NASDAQ: GRCE · Real-Time Price · USD
3.21
0.13 (4.22%)
At close: Aug 15, 2025, 12:23 PM

Grace Therapeutics Balance Sheet Statement

Financials in USD. Fiscal year is April - March.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Mar 31, 2025 Mar 31, 2024 Mar 31, 2023 Mar 31, 2022
Cash & Equivalents
22.13M 23M 27.88M 30.34M
Short-Term Investments
n/a n/a 15K 13.32M
Long-Term Investments
n/a n/a n/a n/a
Other Long-Term Assets
n/a n/a n/a n/a
Receivables
126K 722K 802K 548K
Inventory
n/a n/a n/a n/a
Other Current Assets
n/a n/a n/a 352K
Total Current Assets
22.71M 24.01M 29.29M 45.28M
Property-Plant & Equipment
15K 24K 567K 565K
Goodwill & Intangibles
49.27M 49.27M 49.27M 82.77M
Total Long-Term Assets
49.28M 49.29M 49.83M 83.34M
Total Assets
71.99M 73.3M 79.12M 128.62M
Account Payables
601K 1.01M 1.24M 1.68M
Deferred Revenue
n/a n/a n/a n/a
Short-Term Debt
n/a n/a 75K 104K
Other Current Liabilities
n/a n/a -75K -104K
Total Current Liabilities
1.93M 1.68M 3.41M 3.26M
Long-Term Debt
n/a n/a n/a n/a
Other Long-Term Liabilities
1.14M 4.36M n/a 10K
Total Long-Term Liabilities
3.45M 9.87M 7.76M 17.09M
Total Liabilities
5.38M 11.56M 11.17M 20.35M
Total Debt
n/a n/a 485K 295K
Common Stock
1K 261.04M 258.29M 257.99M
Retained Earnings
-220.69M -211.12M -198.27M -155.84M
Comprehensive Income
-6.04M -6.04M -6.04M -6.04M
Shareholders Equity
66.61M 61.74M 67.95M 108.27M
Total Investments
n/a n/a 15K 13.32M